Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Colombo

Showing results (971-980 of 1,114) with videos related to

Pageof 112
Sort By:
International Journal of Cardiology|April 7, 2018
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry)Cosmo Godino, Alessandro Beneduce, Giuseppe Ferrante, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
JACC. Cardiovascular Interventions|June 23, 2012
A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 yearsPatrick W Serruys, Vasim Farooq, Pascal Vranckx, et al.
Circulation. Cardiovascular Interventions|April 16, 2015
Treatment and clinical outcomes of transcatheter heart valve thrombosisAzeem Latib, Toru Naganuma, Mohamed Abdel-Wahab, et al.
The American Journal of Cardiology|March 23, 2022
Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip InsertionAntonio Sisinni, Andrea Munafò, Carlo Andrea Pivato, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2012
Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) scoreGiuseppe Biondi-Zoccai, Enrico Romagnoli, Davide Castagno, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
JACC. Cardiovascular Interventions|September 20, 2014
Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesisMarco Barbanti, Anna Sonia Petronio, Davide Capodanno, et al.
Pageof 112

Showing results (971-980 of 1,114) with videos related to

Sort By:
Pageof 112
International Journal of Cardiology|April 7, 2018
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry)Cosmo Godino, Alessandro Beneduce, Giuseppe Ferrante, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
JACC. Cardiovascular Interventions|June 23, 2012
A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 yearsPatrick W Serruys, Vasim Farooq, Pascal Vranckx, et al.
Circulation. Cardiovascular Interventions|April 16, 2015
Treatment and clinical outcomes of transcatheter heart valve thrombosisAzeem Latib, Toru Naganuma, Mohamed Abdel-Wahab, et al.
The American Journal of Cardiology|March 23, 2022
Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip InsertionAntonio Sisinni, Andrea Munafò, Carlo Andrea Pivato, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2012
Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) scoreGiuseppe Biondi-Zoccai, Enrico Romagnoli, Davide Castagno, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
JACC. Cardiovascular Interventions|September 20, 2014
Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesisMarco Barbanti, Anna Sonia Petronio, Davide Capodanno, et al.
Pageof 112